MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

    A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

    Objective: To evaluate the safety and efficacy of abobotulinumtoxinA in comparison to onabotulinumtoxinA when used at optimized doses in approved muscles common to both products’…
  • MDS Virtual Congress 2021

    Effects of Gandouling Tablets on the Muscle tone and stiffness of patients with Wilson’s disease: a randomized, double-blind, placebo-controlled study

    W. Hao (Hefei, China)

    Objective: To analyze the effects of Gandouling tablets(GDL) on the tone and stiffness of the biceps brachii muscle in Wilson’s disease (WD) patients, and the correlation between…
  • MDS Virtual Congress 2021

    Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

    F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)

    Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…
  • MDS Virtual Congress 2021

    The Cognitive Features of Idiopathic Cervical Dystonia: a cross-sectional study

    H. Oliveira, S. Camargos (Belo Horzionte, Brazil)

    Objective: To investigate the cognitive performance and the neuropsychiatric profile of patients with idiopathic adult-onset cervical dystonia (CD), to determine the occurrence of neuropsychiatric abnormalities…
  • MDS Virtual Congress 2021

    Cognitive-affective syndrome related to cerebellar hypometabolism secondary to Covid-19 infection : a case report

    S. Potel, M. Merceur, P. Méneret, S. Butet, P. Guillemot, G. Silvestre-Beccarel, I. Bonan, F. Le Jeune, M. Vérin (Rennes, France)

    Objective: To describe a novel case of Covid-19-related cognitive affective syndrome with cerebellar hypometabolism and associated neuropathy. Background: Several Covid-19-related neurological diseases have been described, including…
  • MDS Virtual Congress 2021

    Differentiation of Mild Cognitive Impairment (MCI) progression to Alzheimer Disease (AD) vs Dementia with Lewy Bodies (DLB): Is this possible neuropsychologically?

    P. Voskou (Athens, Greece)

    Objective: Aim of the present review study was to describe and compare the neurocognitive features of MCI which could predict its progression to DLB vs…
  • MDS Virtual Congress 2021

    Carboplatin, Paclitaxel, and Nivolumab-induced Parkinsonism Responsive to Levodopa

    M. Branston, O. Tong (Sacramento, USA)

    Objective: To present the first reported case of reversible, levodopa sensitive, chemotherapy- induced parkinsonism due to the combination of carboplatin, paclitaxel, and nivolumab. Background: Many case reports describe antineoplastic agents causing reversible parkinsonism, most commonly, cyclophosphamide, cytosine arabinoside, and cyclosporine. To our knowledge, drug-induced parkinsonism related to combination therapy of paclitaxel, carboplatin, and nivolumab has never been…
  • MDS Virtual Congress 2021

    Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results

    M. Markota, B. Coombes, J. Leung, R. Savica (Rochester, USA)

    Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…
  • MDS Virtual Congress 2021

    Reanalysis of a Patient-Reported Outcome (Tardive Dyskinesia Impact Scale) Shows Positive Results

    D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)

    Objective: To reanalyze the Tardive Dyskinesia Impact Scale (TDIS) and assess its potential utility in future TD studies. Background: TD is a persistent and potentially…
  • MDS Virtual Congress 2021

    Benefits of Treatment with OnabotulinumtoxinA in Naive and Non-naive Patients with Cervical Dystonia are Sustained over Time: Preliminary Completer Analysis from CD PROBE

    P. Agarwal, M. Schwartz, A. Zuzek, A. Patel (Kirkland, USA)

    Objective: This analysis evaluated the sustained effects of onabotulinumtoxinA in patients with CD who were naive or non-naive to botulinum toxin at enrollment in CD…
  • « Previous Page
  • 1
  • …
  • 704
  • 705
  • 706
  • 707
  • 708
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley